Improving Beta-2 Adrenergic Signaling in Alzheimer's Disease
Status:
Withdrawn
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the effects of long-term therapeutic doses of
formoterol, on a) cerebrospinal fluid (CSF) tau levels, and Amyloid Beta protein 40/42 levels
in the CSF, and b) cognitive function in people with mild to moderate Alzheimer' Disease
(AD).